Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences Thinks Its Own Stock Is a Biotech Bargain

By Motley Fool Staff - May 10, 2016 at 9:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth.

Last quarter, Gilead Sciences (GILD -0.29%) forked over $8 billion to buy back 46 million shares of its stock -- and despite that massive repurchase, the company still plans on spending billions of dollars more on buybacks this year. Does Gilead Sciences' commitment to share repurchases suggest management thinks its stock is the best bargain in biotech? In this clip from the Industry Focus: Healthcare podcast, Motley Fool analyst Kristine Harjes and contributor Todd Campbell discuss Gilead Sciences' plans for its cash stockpile.

A transcript follows the video.

This podcast was recorded on May 4, 2016. 

Kristine Harjes: This is also a company that has quite a bit of cash on the books -- 21 billion at last count. One of our listeners wrote in to This is Mark Fitzgerald of Burlington, Vt. He wrote in asking, pretty much, what Gilead plans to do with all this cash, and whether an acquisition might be in the cards. What do you think, Todd?

Todd Campbell: That's a $21 billion question.

Harjes: It's exactly what it is.

Campbell: Yeah, they have a ton of cash. The funny thing is that cash is after they bought back $8 billion worth of their own stock last quarter.

Harjes: They have been incredibly --

Campbell: ... buy back $8 billion and still have $21 billion in the bank.

Harjes: I'll note, before we move on from that, that was at an average price $92.09 per share, which is 7.6 times 2016 earnings. They're getting their own stock back really, really cheap and they've absolutely implied that they think their own company is the best deal on the market right now, which is why we haven't seen a splashy acquisition.

Campbell: Right, I mean, if you're looking at it and you're saying, OK, you've got companies out there [...] is one that we talked about in the past, that theoretically could be up for sale, that Gilead could walk in and say, "I want to expand into cancer drugs, I'll make a bid for this company." But they're also looking at it and saying, "If management or the board wants too much for that, why don't I just take that money and pour it back into my own stock? I've still got a great business, I can buy it cheap."

Harjes: Yeah, since 2012 they've repurchased 17% of their shares outstanding. I do think that they are looking for external opportunities as well, but for now they don't think they can do any better than Gilead.

Campbell: Right, they're looking for the right deal at the right price. Their oncology team has suffered a few blows recently, because Zydelig's trials got halted because of some safety concerns, and their oncology head has since left. You've got a situation now where they're trying to figure out, "Where do we want to go from here?" While they figure that out, why not just spend that money on dividends and buybacks, right? They increased their dividend by 10%, so they've got plenty of money kicking around that they can use to reward shareholders and that they can continue to plow back into their own drug development. They're working on a drug for NASH, for example, which is another liver disease that could be a huge indication. I think they're spending $3 billion in R&D, so they've got plenty of money kicking around that they can use for future growth.

Harjes: Seems like our answer is pretty much the answer that management actually gives when questioned about this, which is that they'll make the right move when the right opportunity comes. Thanks for helping me answer this one, Todd. If any of other listeners have questions for us feel free, write in at

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.30 (-0.29%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.